These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 27873077)

  • 1. Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes.
    Phimphilai M; Pothacharoen P; Kongtawelert P; Chattipakorn N
    J Bone Miner Metab; 2017 Nov; 35(6):631-641. PubMed ID: 27873077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-Influenced Receptors of Advanced Glycation End Product Overexpression Associated With Osteogenic Differentiation Impairment in Patients With Type 2 Diabetes.
    Phimphilai M; Pothacharoen P; Kongtawelert P
    Front Endocrinol (Lausanne); 2021; 12():726182. PubMed ID: 34512554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptors of Advanced Glycation End Product (RAGE) Suppression Associated With a Preserved Osteogenic Differentiation in Patients With Prediabetes.
    Phimphilai M; Pothacharoen P; Chattipakorn N; Kongtawelert P
    Front Endocrinol (Lausanne); 2022; 13():799872. PubMed ID: 35237235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Taurine Supplementation on Metabolic Profiles, Pentosidine, Soluble Receptor of Advanced Glycation End Products and Methylglyoxal in Adults With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Esmaeili F; Maleki V; Kheirouri S; Alizadeh M
    Can J Diabetes; 2021 Feb; 45(1):39-46. PubMed ID: 32861603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy.
    Ng ZX; Chua KH; Iqbal T; Kuppusamy UR
    Int J Mol Sci; 2013 Apr; 14(4):7480-91. PubMed ID: 23552832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.
    Kurt A; Andican G; Siva ZO; Andican A; Burcak G
    J Physiol Biochem; 2016 Dec; 72(4):679-687. PubMed ID: 27448155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
    Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
    Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
    Haddad M; Knani I; Bouzidi H; Berriche O; Hammami M; Kerkeni M
    Dis Markers; 2016; 2016():6248264. PubMed ID: 27829696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (sRAGE) in Women Suffering from Systemic Lupus Erythematosus (SLE).
    Nowak A; Przywara-Chowaniec B; Damasiewicz-Bodzek A; Blachut D; Nowalany-Kozielska E; Tyrpień-Golder K
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus.
    Farhan SS; Hussain SA
    Diabetes Metab Syndr; 2019; 13(4):2457-2461. PubMed ID: 31405660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary advanced glycated end-products and medicines influence the expression of SIRT1 and DDOST in peripheral mononuclear cells from long-term type 1 diabetes patients.
    Santos-Bezerra DP; Machado-Lima A; Monteiro MB; Admoni SN; Perez RV; Machado CG; Shimizu MH; Cavaleiro AM; Thieme K; Queiroz MS; Machado UF; Giannella-Neto D; Passarelli M; Corrêa-Giannella ML
    Diab Vasc Dis Res; 2018 Jan; 15(1):81-89. PubMed ID: 29027826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study.
    Linssen PB; Henry RM; Schalkwijk CG; Dekker JM; Nijpels G; Brunner-La Rocca HP; Stehouwer CD
    Diab Vasc Dis Res; 2016 Jul; 13(4):278-85. PubMed ID: 27190078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes.
    Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J
    Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes.
    Aubert CE; Michel PL; Gillery P; Jaisson S; Fonfrede M; Morel F; Hartemann A; Bourron O
    Diabetes Metab Res Rev; 2014 Nov; 30(8):679-85. PubMed ID: 24449227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High intake of dietary advanced glycation end-products is associated with increased arterial stiffness and inflammation in subjects with type 2 diabetes.
    Di Pino A; Currenti W; Urbano F; Scicali R; Piro S; Purrello F; Rabuazzo AM
    Nutr Metab Cardiovasc Dis; 2017 Nov; 27(11):978-984. PubMed ID: 28958695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylglyoxal - an advanced glycation end products (AGEs) precursor - Inhibits differentiation of human MSC-derived osteoblasts in vitro independently of receptor for AGEs (RAGE).
    Waqas K; Muller M; Koedam M; El Kadi Y; Zillikens MC; van der Eerden BCJ
    Bone; 2022 Nov; 164():116526. PubMed ID: 35995334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic Fat Content and Liver Enzymes Are Associated with Circulating Free and Protein-Bound Advanced Glycation End Products, Which Are Associated with Low-Grade Inflammation: The CODAM Study.
    Bijnen M; van Greevenbroek MMJ; van der Kallen CJH; Scheijen JL; van de Waarenburg MPH; Stehouwer CDA; Wouters K; Schalkwijk CG
    J Diabetes Res; 2019; 2019():6289831. PubMed ID: 31218233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered expression of a disintegrin and metalloproteinase 10 in peripheral blood mononuclear cells in type 2 diabetes mellitus patients with the acute coronary syndrome: a pilot study.
    Ragavi R; Adole PS; Vinod KV; Pillai AA
    Endocrine; 2022 Sep; 77(3):461-468. PubMed ID: 35877008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies.
    Hanssen NM; Engelen L; Ferreira I; Scheijen JL; Huijberts MS; van Greevenbroek MM; van der Kallen CJ; Dekker JM; Nijpels G; Stehouwer CD; Schalkwijk CG
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1369-73. PubMed ID: 23780372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.